- 全部删除
您的购物车当前为空
Navarixin (MK-7123) 是一种可口服的 CXCR1和 CXCR2变构拮抗剂,对猕猴 CXCR1的 Kd 值为 41 nM,对大小鼠和猕猴 CXCR2的 Kd 值分别为 0.20、0.20 和 0.08 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
Navarixin (MK-7123) 是一种可口服的 CXCR1和 CXCR2变构拮抗剂,对猕猴 CXCR1的 Kd 值为 41 nM,对大小鼠和猕猴 CXCR2的 Kd 值分别为 0.20、0.20 和 0.08 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 388 | In stock | |
| 5 mg | ¥ 816 | In stock | |
| 10 mg | ¥ 1,220 | In stock | |
| 25 mg | ¥ 2,190 | In stock | |
| 50 mg | ¥ 3,290 | In stock | |
| 100 mg | ¥ 4,970 | In stock | |
| 200 mg | ¥ 6,860 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 713 | In stock |
Navarixin 相关产品
| 产品描述 | Navarixin (MK-7123)(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia. |
| 靶点活性 | [125I]-CXCL8-CXCR1:43 nM (IC50), CXCR1 (cynomolgus):41 nM (Kd), [125I]-CXCL8-CXCR2:0.97 nM (IC50), CXCR2 (rat):0.2 nM (Kd), CXCR2 (mouse):0.2 nM (Kd), CXCR2 (cynomolgus):0.08 nM (Kd) |
| 体外活性 | Navarixin is a potent, allosteric antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly[1]. |
| 别名 | SCH 527123, MK-7123 |
| 分子量 | 397.42 |
| 分子式 | C21H23N3O5 |
| CAS No. | 473727-83-2 |
| Smiles | CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 |
| 密度 | 1.34 g/cm3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 55 mg/mL (138.39 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.03 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容